A Nature Medicine review published in January 2026 described GLP-1 medicines as "being prescribed to growing numbers of patients worldwide" for an expanding list of indications and noted that "new, more effective molecules with optimised pharmacokinetics produce greater weight loss and some may be more effective for various metabolic disorders, through incorporation of one or more additional peptide epitopes." The clinical pipeline includes 39 GLP-1 receptor agonist drugs in development across 34 companies, with only seven coming from the top 20 pharmaceutical firms
GHK-Cu's collagen synthesis and fibroblast-stimulation literature makes it the natural anchor for a skin-focused research formulation
Additionally, obesity-related inflammation affects the ovaries and induces physiological changes due to IS impairment
"I trained at the highest level, ate a clean diet, pushed myself, and still, after having kids, my body just wouldn't respond
Presented for research literature review only Sills ES et al